An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

Meibomian Gland Dysfunction (MGD) Clinical Trial

Official title:
A Single-center, Vehicle-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZR-MD-001 as Adjunctive Therapy to Conventional Therapeutic Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

Status Completed

Clinical Trial Summary

SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).

Clinical Trial Description

SOVS2019-070 is a single-center, single-masked (the individual(s) performing efficacy measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized, parallel group study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03972501
Study type	Interventional
Source	Azura Ophthalmics
Contact
Status	Completed
Phase	Phase 2
Start date	October 4, 2019
Completion date	December 11, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01683318` - Treatment of Meibomian Gland Dysfunction	N/A
Completed	`NCT03708367` - A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice	N/A
Completed	`NCT02284997` - The Effect of an Eyelid Warming Device for the Management of Meibomian Gland Dysfunction	N/A